Breakthrough Designation Affirms Ocrelizumab Blockbuster Potential and Sets Ocrelizumab up for Approval and Launch by the End of 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "CNS Drug News Issue 373" report to their offering.

Ocrelizumab has blockbuster potential as the first therapeutic to control primary progressive multiple sclerosis. There is a high demand for therapeutics to manage the condition and ocrelizumab will see significant and rapid sales growth. Breakthrough designation confirms a high level of confidence in the drug's ability to manage the condition and sets ocrelizumab up for approval and launch by the end of 2017.

Key Topics Covered:

1. Neurodegenerative Disorders

  • Parkinson's Disease
  • LCT Completes Private Placement Of Shares
  • Xadago Launched In Spain To Treat Mid- To Late-Stage PD
  • Open Innovation Tools Crucial For Parkinson's Disease Therapy Advancement
  • Billion Dollar Revenues Beckoning For Impax
  • Alzheimer's Disease
  • ANI And Dexcel Gain Donepezil Approval
  • Other Neurodegenerative Disorders
  • US Investment Lays MTP Global Expansion Groundwork
  • Retrophin's RE-024 Granted European ODD To Treat PKAN

2. Cerebrovascular Disorders

  • MultiStem Cell Therapy Phase II Stroke Study Yield Positive Results

3. Antidepressants

  • Novel Drug Delivery Techniques Could Aid MDD Development

4. Psychotic Disorders

  • FDA Approves Impax' Mixed Amphetamines ANDA
  • Alexza Regains Adasuve US Rights From Teva

5. Analgesics/Anaesthetics

  • Lannett Gains Sumatriptan Nasal Spray Approval
  • Dosing Begins In CAM2038 Phase II Study In Opioid Dependent Patients
  • Belbuca Buccal Film Launched In US For Chronic Pain Management
  • FDA Breakthrough Therapy Designation For Trevena's Oliceridine

6. Therapies to Treat Substance Dependence

  • Adapt Pharma's Narcan Nasal Spray Now Available In US

7. Anti-Epileptics

  • Aequus/Supernus Enter Licensing Deal For Trokendi/Oxtellar In Canada
  • Briviact Approval Vital To Retain US Epilepsy Market Position
  • Neurelis Finalises Funding To Advance NRL-1 NDA Filing
  • FDA Approves Intellipharmaceutics' Levetiracetam
  • E Keppra Granted Japanese Approval In Certain Generalised Tonic-Clonic Seizures Patients

8. Eating Disorders

  • Mixed Trial Results Will Make Risk Management Key For Future Beloranib Development

9. General Development News

  • FDA ODD For Remedy's Cirara In Acute SAH/SCI
  • Neuroscience IVDs Remain An Untapped Market
  • Fresh Data Further Undermines Addyi Earnings Potential

10. Corporate Activity

  • Rising Trial Risk Will Promote Novel Methods Of Drug Development
  • Lightlake Changes Name To Opiant Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/c2pxr3/cns_drug_news

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs